• Betadine® - Iodine-based antiseptic for treatment and prevention of infections in the skin and mucous membranes. Betadine® is the market leader in several European countries.


  • Novopulmon® is an anti-inflammatory corticosteroid (budesonide) with the Novolizer® device for treatment of asthma and COPD .

  • Astepro® is a novel intranasal antihistamine for the treatment for allergic rhinitis.  It has been launched in the USA and it’s in registration phase in Europe.


  • Tambocor® is an antiarrhythmic drug and the market leader in several European countries.


  • EpiPen®  is used for emergency treatment of severe allergic reactions (anaphylaxis) that can occur rapidly and be life-threatening.

  •  


    SB12®  - Controlled breath for 12 hours. SB12 is an oral care agent that neutralizes the substances that causes bad breath.

Dividend

The AGM declared a dividend of two and twentyfive (2.25) kronor per share. The dividend is expected to be distributed under the direction of Euroclear Sweden AB on May 18, 2012. Meda traded ex dividend May 10.